Daniel-Paul Bednarík, Ph.D. Email & Phone Number

Highland, Md, Us

Currently assisting with the financing and technology development for the new company in a contract consulting position.

Gaithersburg, M.D, Us

I am serving as a molecular and protein design consultant.

Philadelphia, Pa, Us

Focused on the translational biology of heart function and disease states.

NexImmune, is an early stage biopharmaceutical company, grounds its novel technology on the discoveries from the laboratory of Drs. Jonathan Schneck and Mathias Oelke of The Johns Hopkins University, both Scientific Co-founders of NexImmune, that reports the development of a new approach for adoptive cellular therapy. In this study artificial Antigen Presenting Cells (aAPC) were used to stimulate rapid ex-vivo Enrichment and Expansion (E+E) of tumor-specific T cells. Within a two-week period, these cancer fighting cells were expanded to numbers that represent potentially therapeutic levels – when they could be adoptively transfused back into a patient in the form of cellular immunotherapy. This new technology can also be used to validate patient-specific neoantigens. Neoantigens are formed as a result of mutations arising in cancer cells and can be detected by a patient’s T cells with the same strength as they may detect microbial antigens. Neoantigens have recently been described as clinically desirable targets for the development of personalized cancer immunotherapies.

NexImmune, an early stage biopharmaceutical company, grounds its novel technology on the discoveries from the laboratory of Dr. Jonathan Schneck of The Johns Hopkins University, a Scientific Co-founder of NexImmune, that reports the development of a new approach for adoptive cellular therapy. In this study artificial Antigen Presenting Cells (aAPC) were used to stimulate rapid ex-vivo Enrichment and Expansion (E+E) of tumor-specific T cells. Within a two-week period, these cancer fighting cells were expanded to numbers that represent potentially therapeutic levels – when they could be adoptively transfused back into a patient in the form of cellular immunotherapy. This new technology can also be used to validate patient-specific neoantigens. Neoantigens are formed as a result of mutations arising in cancer cells and can be detected by a patient’s T cells with the same strength as they may detect microbial antigens. Neoantigens have recently been described as clinically desirable targets for the development of personalized cancer immunotherapies.

Bozeman, Montana, Us

Microbion’s bismuth-thiol (BT) family of compounds have potent, broad spectrum efficacy against all antibiotic resistant bacteria tested to date. Additionally they have the highly advantageous and product-differentiating capability to prevent and eradicate microbial biofilms. Their effectiveness against MRSA, MDR TB, CRE, VRE, and other antibiotic resistant pathogens highlights their potential to provide solutions to the dramatic and alarming increase in global antibiotic resistance.

Silver Spring, Md, Us

BioIT is a Silver Spring Maryland-based software company specializing in Biotechnology applications, providing a novel line of Portal Products. The founders of BioIT originated from Human Genome Sciences, Inc. (HGS) where the CIO, Michael Fannon, served as the primary architect and designer of that company's cutting edge bioinformatic database and genomics tools. My role with BioIT is to help extend product development and bring this unique capability to clients in the biotechnology and pharmaceutical industry on a customized basis. My experience with bioinformatics and genomics provides BioIT with new potential user bases and development of new functionality.

Development of stable cell lines for company's RCB and MCB. Expression of nicotine monoclonal antibodies that facilitate smoking cessation.

Germantown, Maryland, Us

Promoted to Vice President in August, 2013 #Daniel Bednarik -- Oversees the operations of the company's Molecular Engineering Unit and synthetic biology programs, with emphasis on new gene switch designs and their translation to immuno-oncology and adoptive T-cell therapies (CAR-T). Works closely with the Health Sector Division head and Senior Management and is a member of the Executive Committee led by Randal J. Kirk (Chairman & CEO). The MEU employs Intrexon's proprietary technologies that grounds the company's commercial efforts for synthetic biology approaches to treat cancer, and other diseases. The MEU serves as a central nexus to support all corporate divisions programs. Addresses molecular technology needs to foster partnerships, new business development opportunities, and ensures MEU processes are optimized to maintain seamless operation for both company and external partners. See http://www.dna.com/OurApproach/Process/CoreTechnologyUnits for the current MEU mission.

Germantown, Maryland, Us

Oversees the company's Molecular Engineering Unit and program. Works closely with the COO, CSO, President of the Human Therapeutics Division (HTD), Senior Director of Translational Research, Business Development, and Cell Engineering Unit (CEU). The MEU employs Intrexon's proprietary "Ultravector Technology" that grounds the company's commercial efforts for gene therapy, multigenic gene program expression, and synthetic biology for treatment of cancer, and other diseases. The MEU is a pivotal facilitator of Translational Medicine/Research for Intrexon. Addresses molecular technology needs to foster partnerships, new business development opportunities, and ensures MEU processes are optimized to maintain seamless operation for both company and external partners. Dr. Bednarik and his team speialize in therapeutic miRNA solutions. www.dna.com

I was acquired by Cardiome initially as a consultant to transition the Artesian assets into the company for two years, then hired by the company. I worked for Cardiome in total for 7 years. Cardiome is a research-based biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the quality of life and health of patients. We strive to find innovative medicines that provide value to patients, physicians and healthcare systems. While working for Cardiome, I have focused efforts on development of new biomarker-driven efforts to simplify clinical trial stratification.I conceived and launched the Cardiome Antiviral Discovery program - This program couples the discovery and development of "first in class" antiviral small molecules to target a unique ion channel called the "Viroporins". Cardiome's strength in ion channel biology is expected to put a new face on the therapeutic targeting of these proteins. This program received funding through a grant awarded by the Canadian Institutes of Health Research (CIHR) - $500,000 (CAD) per year for 3 years.

Post-acquisition responsibilities included transition of CRPM and BRPM programs into Cardiome Pharma Corp., acting as Program Manager and designing new animal studies for therapeutic compound validation.

The company's lead siRNA and antisense DNA delivery product, Versadel, is undergoing pre-clinical testing with the intention of partnering with major pharmas. My role for Ablitech is to establish and organize the Scientific Advisory Board (SAB) and assist in the critique of ongoing scientific projects.

Indel Therapeutics Inc. is a biopharmaceutical company dedicated to developing new drugs to address the global health crisis caused by antibiotic resistance. The Company has a growing pipeline of novel antibiotic drug discovery programs that focus on curing difficult-to-treat and hospital-acquired infections. These programs are based on Indel’s paradigm-changing antimicrobial drug discovery platform, a patented technology that has opened a rich, new area of drug targets for the treatment of bacterial and parasitic infections and, potentially, fungal and viral infections.My role for Indel Therapeutics has been to identify new opportunities, assist in the company's interface with the US Dept. of Defense, and provide insights and advice regarding bioinformatics, database development, and recruitment of funding.See - www.indelrx.com

NX PharmaGen’s groundbreaking technologies are paving the way for patients to realize the promise of personalized medicine in cancer and other diseases. The company employs a novel approach to predictive molecular diagnostics by profiling a unique class of biological messengers called "exosomes" or "microvesicles". My role has been to support the scientific aspects of product development as well as the bioinformatic needs and objectives of the company.See - www.nxpharmagen.com

Paris, Fr

Directed new business development efforts, partnering, and translation of corporate technology to practice in the business sector. Worked directly with Vice President, Business Development and Vice President of R&D to execute database partnering opportunities.

Consulting for drug development.

Served as co-founder of company spin out from Gene Logic, Inc. in 2002. Quickly defined relationships between dysregulation of gene expression and small molecule SAR. The program led to two therapeutic classes of molecules designed to restore ejection of blood to the failing heart while suppressing beta-agonist pathways. This led to a rapid exit via sale of the company to Cardiome Pharma Corp. in October, 2005.

Gaithersburg, Md, Us

Dr. Bednarik created the largest known cardiovascular gene expression database for Gene Logic, which served as a prized source of cardiovascular disease data for multiple pharma companies, and grounded the basis for founding Artesian Therapeutics. This database integrated unique personal and clinical biosample attributes with changes in gene expression in disease-vs-normal cardiovascular tissues derived from man and animal model systems. Along with other disease programs at Gene Logic, it propelled a revolution in disease pathway and drug discovery.

Pre-clinical study development and reporting for the medical device and pharmaceutical industry.

Served as molecular biologist and bioinformatics scientist - Discovery, characterization, and patenting of novel genes for development of therapeutic proteins.

Msc, Phd, Biochemistry

Oncology Fellow, Oncology And Cancer Biology/Virology

Ba, Biology

High School Diploma